

# Contribution of (1→3)-β-D-Glucan Chromogenic Assay to Diagnosis and Therapeutic Monitoring of Invasive Aspergillosis in Neutropenic Adult Patients: a Comparison with Serial Screening for Circulating Galactomannan

Carmen Pazos,<sup>1\*</sup> José Pontón,<sup>2</sup> and Amalia Del Palacio<sup>1</sup>

Unidad de Micología, Departamento de Microbiología, Hospital Universitario 12 de Octubre, Madrid,<sup>1</sup> and Departamento de Inmunología, Microbiología y Parasitología, Facultad de Medicina y Odontología, Universidad del País Vasco, Bilbao, Vizcaya,<sup>2</sup> Spain

Received 8 July 2004/Returned for modification 4 August 2004/Accepted 18 September 2004

**Two noninvasive diagnostic tests, (1→3)-β-D-glucan (BG) (GlucateLL) and galactomannan (GM) (Platelia *Aspergillus*), were used retrospectively in a twice-weekly screening for the diagnosis of invasive aspergillosis (IA) in 40 treatment episodes (one hospital visit per patient) in 40 neutropenic adult patients at high risk for IA. Five proven IA cases, three probable IA cases, and three possible IA cases were diagnosed. Diagnostic levels of both BG and GM were detected in 100% of patients with proven IA cases and in 66% of patients with probable IA cases. The kinetics of both markers in patients with IA were similar. The sensitivity, specificity, and positive and negative predictive values for GM and BG were identical, namely, 87.5, 89.6, 70, and 96.3%, respectively. False-positive reactions occurred at a rate of 10.3% in both tests, but the patients showing false-positive results were different in each test. Both tests anticipated the clinical diagnosis, computed tomography abnormalities, and the initiation of antifungal therapy in most patients, but BG tended to become positive earlier than GM. A combination of the two tests improved the specificity (to 100%) and positive predictive value (to 100%) of each individual test without affecting the sensitivity and negative predictive values. In conclusion, BG and GM detection are useful tests for the diagnosis of IA in high-risk hematological patients, but a combination of the two tests was very useful to identify false-positive reactions by each test.**

Invasive aspergillosis (IA) is an increasingly common infection among hematological cancer patients receiving cytotoxic chemotherapy (7, 34). Steroid-treated allogeneic bone marrow transplant recipients are particularly at risk (10, 19). The crude mortality rate of IA is very high despite appropriate antifungal treatment, since the difficulty in obtaining an early diagnosis results in a delay in establishing treatment (15). The diagnosis of IA is frequently established postmortem. Prompt initiation of antifungal therapy in patients with IA is critical in improving the outcome of this disease (37). Conventional diagnostic methods are insensitive, and the “gold standard” diagnostic procedures (histological examination and cultures of deep tissues) require an aggressive approach which often precludes their use due to profound thrombocytopenia, hypoxemia, and the critical condition of these patients (1).

Clinically, IA is nonspecific, and clinical and radiological signs appear late in the course of the infection (11). In recent years a number of rapid diagnostic techniques have become available: high-resolution computed tomography (HRCT) and non-culture-based methods such as detection of circulating fungal antigens and nucleic acids. These techniques, when combined with risk stratification as described by Prentice et al. (27), permit the early diagnosis of IA and the implementation of preemptive therapeutic strategies. The rapid serological di-

agnostic methods appear to be most useful when used prospectively to screen high-risk patients (11). Several prospective clinical trials with neutropenic patients have shown the utility of *Aspergillus* galactomannan (GM) detection by enzyme immunoassay (ELISA) (Platelia *Aspergillus*; Bio-Rad, Marnes-La-Coquette, France) for the early diagnosis of IA (13, 16–18, 25, 31, 35, 36).

(1→3)-β-D-Glucan (BG) is a cell wall polysaccharide component specific for fungi except for zygomycetes and, to a lesser extent, cryptococci (21). Prokaryotes and viruses, as well as human cells, lack BG. Its presence in blood and normally sterile body fluids may be a marker of invasive fungal infection (IFI) including infection with the most common pathogens such as *Aspergillus* and *Candida*. Although there are a number of commercially available methods to detect BG (FungiTec G, Seikagaku Kogyo Corp., Tokyo, Japan; β-D-glucan Test Wako, Wako Pure Chemical Industries, Tokyo, Japan; B-G Star, Maruha Corp., Tokyo, Japan), there is little experience in the use of this marker outside Japan. A new chromogenic test to detect BG (GlucateLL; Associates of Cape Cod, Falmouth, Mass.) has been recently commercialized, and a preliminary study has documented its potential for the diagnosis of IFI in humans (24).

The aim of this study was to assess the usefulness of BG detection in sera by the GlucateLL test for the diagnosis and therapeutic monitoring of IA in neutropenic adult patients at increased risk for IA. BG detection was compared with the widely used GM detection in an attempt to study the kinetics of both markers and to assess whether a combination of the tests may result in an early and specific diagnosis of IA.

\* Corresponding author. Mailing address: Unidad de Micología, Departamento de Microbiología, Hospital Universitario 12 de Octubre, Avenida de Córdoba s/n, 28041 Madrid, Spain. Phone: 34-91-390-8239. Fax: 34-91-565-2765. E-mail: pazos.c@terra.es.

TABLE 1. Characteristics of patients with proven, probable, and possible IA

Patient no.	Gender/age (yr) <sup>a</sup>	Underlying disease <sup>b</sup>	Type of IA	Steroids <sup>c</sup>	Duration of neutropenia (days)	No. of positive samples/total no. of samples	Highest level of glucan (pg/ml)	Organ involvement of IA	Site(s) of isolation/ <i>Aspergillus</i> species <sup>b</sup>	HRCT scan	Death in relation to IA
1	M/70	MDS	Proven	–	26	9/13	>523	Lungs	TBB/ <i>A. fumigatus</i>	Nodules in lungs	No
2	F/65	NHL	Proven	+	10	3/6	>523	Lungs	TBB/ <i>A. fumigatus</i>	Nodules in lungs	Yes
3	F/29	AML	Proven	+	34	9/6	>523	Lungs, brain	Sputum/ <i>A. fumigatus</i> Abscess/ <i>A. fumigatus</i>	Nodules in lung Pleural effusion	No
4	F/30	AML	Proven	–	66	10/24	>523	Lungs, subcutaneous tissue	Subcutaneous nodule/ <i>A. flavus</i>	Nodules in lungs	No
5	F/44	CLL	Proven	+	32	4/12	>523	Lungs	TBB/ <i>A. fumigatus</i>	Bilateral infiltrate in lungs	No
6	M/45	AML	Probable	+	30	0/9		Lungs	BAL/ <i>A. fumigatus</i>	Nodules in lungs	No
7	M/70	MDS	Probable	+	23	8/18	>523	Lungs	Sputum/ <i>A. fumigatus</i>	Nodules in lungs	No
8	F/32	AML	Probable	+	26	9/9	>523	Lungs Pleural effusion	Sputum/ <i>A. fumigatus</i>	Nodules in lungs	Yes
9	M/20	ALL	Possible	–	28	0/8		Lungs		Nodule in lungs	No
10	M/25	ALL	Possible	+	31	0/14		Lungs		Nodules in lungs	No
11	F/54	AML	Possible	–	60	12/16	>523	Lungs		Pleural effusion	Yes

<sup>a</sup> M, male; F, female.

<sup>b</sup> MDS, myelodysplastic syndrome; NHL, non-Hodgkin's lymphoma; AML, acute myelogenous leukemia; CLL, chronic lymphocytic leukemia; ALL, acute lymphocytic leukemia; TBB, transbronchial biopsy.

<sup>c</sup> +, administered; –, not administered.

## MATERIALS AND METHODS

**Patient selection.** From April 2001 to June 2002, all adult hematological cancer patients ( $n = 154$ ) treated at the Hospital 12 de Octubre, Madrid, Spain, and stratified as high-risk individuals as defined by Prentice et al. (27), were prospectively analyzed twice weekly for quantitative values of GM by using the commercially available sandwich ELISA (Platelia *Aspergillus*) until the high-risk condition for developing IFI had subsided. The prospective study aiming to evaluate the value of GM in the diagnosis of IA has been published elsewhere (25). The availability of serial serum samples together with complete clinical records gave us the opportunity to assess retrospectively the usefulness of the GlucateLL test for the diagnosis of IA in a selection of 40 patients, including 5 with proven IA, 3 with probable IA, 3 with possible IA, and 29 without IA. The patient characteristics and sample distributions are summarized in Tables 1 and 2.

**Definition of invasive aspergillosis.** IA episodes were classified on the basis of the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC-IFIG and NIAID-MSG) case definitions (1). In the prospective study (25), GM results were excluded as microbiological criteria.

**Diagnostic work-up of IFI.** In cases of clinical suspicion of IFI, or when the GM index was above 1.5, a diagnostic work-up was started; this included a pulmonary HRCT scan followed, when possible, by bronchoalveolar lavage and/or biopsy for bacterial, mycobacterial, fungal, and viral cultures. Direct examination for bacteria and fungi (including *Pneumocystis jirovecii*) was performed for all patients. The presence of *Legionella* antigen in urine was tested.

**Management of patients.** All patients were nursed in rooms with HEPA filtration. Antifungal prophylaxis with fluconazole (200 mg once daily) was given to 9 (22.5%) of 40 patients. One patient (2.5%) with possible IA (patient 11, Table 1) received prophylactic liposomal amphotericin B because she had had a previous episode of possible IA, and another patient (2.5%) with proven IA (patient 2, Table 1) received itraconazole due to a previous episode of *Aspergillus* tracheobronchitis. Initial antibiotics for febrile neutropenia included a  $\beta$ -lactam and aminoglycoside; vancomycin was added 48 h later if fever persisted. Antimicrobial therapy could be modified on the basis of microbiological findings. Criteria for initiating antifungal therapy with liposomal amphotericin B included (i) persistent fever after 5 days of intravenous antibiotic treatment, (ii) development of pulmonary infiltrates while receiving antibacterial therapy, (iii) isolation of mycelial fungi from the respiratory tract, and (iv) recurrence of fever after an afebrile interval of at least 48 h in neutropenic patients still receiving broad-spectrum antibiotics.

**Collection and storage of serum samples.** Blood samples (5 ml of whole blood) were collected by venipuncture twice weekly until the risk for IFI had ended. Serum was separated from the blood and tested prospectively twice weekly for GM, and serum samples were stored frozen at  $-70^{\circ}\text{C}$  until tested for BG.

**BG detection.** BG was detected with the GlucateLL test kit essentially as recommended by the manufacturer. Briefly, serum samples (5  $\mu\text{l}$ ) were pretreated for 10 min at  $37^{\circ}\text{C}$  with 20  $\mu\text{l}$  of a solution containing 0.6 M KCl and 0.125 M KOH and assayed with the GlucateLL reagent in a kinetic, chromogenic format for 25 to 40 minutes at  $37^{\circ}\text{C}$ . Optical densities at 405 nm ( $\text{OD}_{405}$ ) were read. The concentration of BG in each sample was calculated by using a calibration curve with standard solutions of 6.25 to 100 pg/ml. Patients were judged positive if the level of BG was  $\geq 120$  pg/ml in at least one serum sample.

**GM detection.** The ELISA was performed as recommended by the manufacturer in Europe (32). Results were expressed as the ratio of the OD obtained from the patient serum sample and the control (index = OD of the sample/OD of the control). A result was considered a true positive when two consecutive samples for a patient tested positive, including the retesting of the first sample (an index of 1.5 or greater was considered positive). Results between 1.0 and 1.5 (gray zone) were considered undetermined. An index below 1.0 was negative.

**Surveillance cultures.** Semiquantitative surveillance cultures for yeasts were performed weekly. Oropharyngeal, nasal, perineal skin, vulvovaginal or balanopreputal, rectal, and pericatheter skin specimens were planted onto CHROMagar and Sabouraud chloramphenicol (0.4 g/liter), and the plates were incubated at  $37^{\circ}\text{C}$  for 2 weeks. Cultures were evaluated using the following score: negative (0 colonies), light (<10 colonies), moderate (11 to 20 colonies), and heavy (>20 colonies). The yeast isolates were identified by the API 32 system (Bio-Mérieux, Marcy L'Etoile, France).

**Mycological studies.** When judged necessary, specimens from clinically infected foci were collected and processed as described by Denning et al. (6). Blood samples for culture were inoculated in a BACTEC Plus aerobic/F bottle and incubated for up to 15 days with the BACTEC 9240 blood culture system (Becton Dickinson Franklin Lakes, N.J.). *Aspergillus* species were identified by their macroscopic and microscopic culture characteristics.

**Statistical analysis.** Sensitivity, specificity, and positive and negative predictive values were calculated as described by Kozinn et al. (14). According to Mennink-Kersten et al. (20), only proven and probable IA were considered truly positive and only no IA cases were considered truly negative.

## RESULTS

**BG detection.** Of 40 patients, 11 (27.5%) had BG levels of  $\geq 120$  pg/ml in at least one serum sample. In most patients, BG positivity was detected in two or more samples (median, 6.4 positive serum samples per patient). All five patients with proven IA (100%), two (66%) of three patients with probable IA, and one (33%) of three patients with possible IA tested

TABLE 2. Characteristics of patients at risk for IA in whom serum BG and GM was evaluated

Characteristic	Proven IA	Probable IA	Possible IA	No IA	Total
No. of patients	5	3	3	29	40
Age (yr) <sup>a</sup>	48 (29–70)	49 (32–70)	33 (20–54)	45 (18–70)	44 (18–70)
Gender (M/F) <sup>b</sup>	2/3	2/1	2/1	17/12	23/17
No. (%) with underlying disease <sup>c</sup>					
ALL			2 (66.7)		2 (5)
AML	2 (40)	2 (66.7)	1 (33.3)	4 (13.8)	9 (22.5)
CLL	1 (20)			8 (27.5)	9 (22.5)
MM				3 (10.34)	3 (7.5)
MDS	1 (20)	1 (33.3)		1 (3.4)	3 (7.5)
NHL	1 (20)			8 (27.6)	9 (22.5)
HD				4 (13.8)	4 (10)
SAA				1 (3.4)	1 (2.5)
No. (%) receiving steroids	3 (60)	3 (100)	1 (33.3)	6 (20.7)	13 (32.5)
Mean duration of neutropenia (days)	42.8	37.33	43.6	22.44	27.7
Range of duration of neutropenia (days)	10–70	27–56	26–56	6–70	6–70
No. of episodes of antifungal therapy	5 (100)	3 (100)	3 (100)	12 (30)	23 (57.5)
No. of samples (total)	69	36	39	181	325
No. of samples/episode	13.8	12	12.66	6.24	8.12
No. <sup>d</sup> (%) of positive episodes	5 (100)	2 (66)	1 (33)	3 (10.34)	11 (27.5)
No. (%) of positive samples for BG	35 (50.7)	17 (47.2)	12 (30.7)	6 (3.3)	64 (19.7)
No. (%) of positive samples for GM	28 (40.6)	13 (36.1)	11 (28.2)	6 (3.3)	58 (17.8)

<sup>a</sup> Values in parentheses are ranges.

<sup>b</sup> M/F, male/female.

<sup>c</sup> ALL, acute lymphocytic leukemia; AML, acute myeloid leukemia; CLL, Chronic lymphocytic leukemia; MM, Multiple myeloma; MDS, Myelodysplastic syndrome; NHL, Non-Hodgkin's lymphoma; HD, Hodgkin disease; SAA, Severe aplastic anemia.

<sup>d</sup> Values in parentheses are percentages of patients who received antifungal therapy.

positive for BG (Tables 1 and 2). In patients with proven IA, BG levels showed a constant rise before clinical and microbiological evidence of IA existed and then decreased and eventually became negative if the patient responded to antifungal therapy (Fig. 1a). However, patients not responding to antifungal treatment did not show a decrease in the levels of BG (Fig. 1b).

Of 29 patients with no IA, 3 (10.3%) were positive for BG detection. In these three patients, IFI was excluded after the careful assessment of clinical, microbiological, and radiological records and outcome of the patients without antifungal treatment. None of these patients had mucositis. The first patient was not colonized by yeasts but had *Escherichia coli* bacteremia. The second patient had a single site colonized with *Candida albicans* (low count), and the third individual had high counts of both *C. albicans* and *Candida glabrata* in four different sites. Although the theoretical occurrence of invasive candidiasis in the last two patients cannot be ruled out, the likelihood of invasive candidiasis was very low because neither patient had antibodies to *Candida albicans* germ tubes (CAGT) (reference 9 and data not shown). Analysis of the kinetics of BG levels helped in the identification of false-positive results since in these patients BG levels showed abrupt rises and falls. An example of this type of kinetics is shown in Fig. 1c, where high levels of BG were detected in a patient with multiple myeloma at the time *E. coli* was isolated in a blood culture. BG levels became negative during the following days in the absence of any antifungal treatment. Most patients with

no IA showed very low levels of BG during the period studied (Fig. 1e and f).

The temporal relationship between positive BG values in serum and other findings in patients with proven and probable IA is shown in Table 3. BG preceded ( $n = 2$ ) the development of fever by 4 and 6 days. One febrile patient with probable IA had negative BG antigenemia. This patient had acute myeloid leukemia and *E. coli* bacteremia. After observation of pulmonary nodules in the HRCT scan and the growth of *A. fumigatus* in bronchoalveolar lavage fluid, the patient was treated with amphotericin B. BG preceded ( $n = 4$ ) the development of clinical signs (cough and/or dyspnea and/or hemoptysis and/or thoracic pain) by 4, 10, 8, and 21 days. A positive BG result preceded the demonstration of abnormalities on HRCT scan in all seven patients (100%) by a median of 9.3 days (range, 1 to 21 days). Positive BG results preceded the initiation of antifungal therapy in five patients by a median of 14 days (range, 4 to 25 days).

Considering true positives as only the results obtained for patients with proven and probable IA cases and true negatives as the results in the no-IA group of patients, the sensitivity, specificity, and positive and negative predictive values of BG monitoring were 87.5, 89.6, 70, and 96.3%, respectively.

**GM detection.** Of 40 patients, 11 (27.5%) repeatedly tested positive for GM detection. This group of GM-positive patients included 100% of patients with IA (five of five), 66% of patients with probable IA (two of three), and 33% of patients with possible IA (one of three) (Table 2). Of 29 patients with




FIG. 1. Representative kinetics of BG (●) and GM (◆) in different patients. (a) Proven IA in a patient with acute myeloid leukemia who responded to treatment with amphotericin B and caspofungin. (b) Proven IA in a patient with chronic lymphocytic leukemia who did not respond to treatment with amphotericin B. (c) False-positive BG results in a patient with multiple myeloma and no IA. (d) False-positive GM results in a patient with non-Hodgkin's lymphoma and no IA. (e) Negative BG and GM results in a patient with acute myeloid leukemia and no IA who was colonized by *C. albicans* and *C. glabrata*. (f) Negative BG and GM results in a patient with chronic lymphocytic leukemia and no IA who was colonized by *C. albicans*. Abbreviations: AmB, amphotericin B; Caspo, caspofungin.

no IA, 3 (10.3%) were positive for GM detection. One of these patients with false-positive results had a relapse of acute myelogenous leukemia and severe mucositis, cytomegalovirus viremia, and graft-versus-host disease. The second patient had acute myelogenous leukemia, severe mucositis, and *Pseudomonas aeruginosa* bacteriemia. The third patient had Hodgkin's lymphoma and *Staphylococcus aureus* and *Staphylococcus epidermidis* bacteremia and had been treated with cyclophosphamide (Fig. 1d).

Considering true positives as only the results obtained for patients with proven and probable IA cases and true negatives as the results in the no-IA group of patients, the sensitivity, specificity, and positive and negative predictive values of GM monitoring were 87.5, 89.6, 70, and 96.3%, respectively.

The temporal relationship between GM antigenemia and other diagnostic markers in patients with proven and probable IA is shown in Table 4. Antigen GM detection preceded the

development of fever by 4 days in one patient. GM antigenemia preceded the development of clinical signs ( $n = 3$ ) by 4, 8, and 15 days. Antigen GM detection preceded the demonstration of abnormalities in HRCT scans in six patients by a median of 7.2 days (range, 1 to 15 days). Positive GM antigenemia preceded the initiation of antifungal therapy in four patients by a median of 12.5 days (range, 1 to 23 days).

**Combined analysis of both markers.** The results obtained by BG and GM detection in each patient were combined in an attempt to assess whether a combination of the two markers resulted in an early and specific diagnosis of IA. Interestingly, both tests were positive in the same patients with IA and the kinetics of both markers were very similar in most patients. BG tended to become positive earlier than GM. Discrepancies were observed in patients with false-positive results, since patients without IA but positive for BG detection were negative by GM detection and patients with false-positive results for



TABLE 3. Temporal onset of BG antigenemia in patients with proven and probable IA

Time point <sup>a</sup>	No. of evaluable patients	No (%) of patients with BG antigen	Days between BG detection and time point median (range)
First day of fever	7	2 (28.2)	5 (4–6)
First day of clinical signs <sup>b</sup>	7	4 (57.1)	10.7 (4–21)
Pulmonary HRCT scan	7	7 (100)	9.3 (1–21)
Initiation of antifungal therapy	7	5 (71.4)	14 (4–25)

<sup>a</sup> At or before time point.<sup>b</sup> Cough and/or dyspnea and/or hemoptysis and/or thoracic pain.

GM were negative by BG detection. Interestingly, these discrepancies were important to identify the patients with false-positive results since it was only when both markers were positive that the patients had IA.

Consideration of the results obtained for both markers in combination showed in an improvement of the diagnostic efficacy of each individual test to predict IA. The sensitivity, specificity, and positive and negative predictive values were 87.5, 100, 100, and 96.3%, respectively.

## DISCUSSION

IA is one of the most frequent fungal infections in neutropenic patients, in whom it is a major cause of morbidity and mortality, in part due to the inability to identify infected patients at an early stage of the disease (4, 5). The diagnosis of IA is a challenge for the clinician, as are the poor prognosis and the limited efficacy of current available antifungal drugs (7). Traditional microbiological studies (direct microscopy and culture of respiratory specimens) have low sensitivity and appear positive only in the late stage of IA. Furthermore, positive cultures do not discriminate between colonization, contamination, and IA (26). In recent years, the detection of different circulating surrogate markers such as fungal cell wall components (BG and GM) and genomic fungal DNA have emerged and improved the diagnosis of IA (5, 13, 20, 26, 28). The Platelia *Aspergillus* kit for the detection of GM has been widely used in Europe for several years, and the Food and Drug Administration has recently approved its clinical use in the United States (5, 11, 13, 16–18, 25, 28, 31, 32, 35, 36). While the prospective detection of GM in patients at high risk for IA

shows that the Platelia *Aspergillus* test is highly specific (above 85%), the reported sensitivity varies widely, between 30 and 100%, due to several factors discussed by Mennink-Kersten et al. (20). One of these factors is the cutoff value of a positive GM result. In Europe the manufacturer recommends a cutoff of 1.5 ng/ml, while in the United States 0.5 ng/ml is the recommended value.

A strategy to overcome the deficiencies of the Platelia *Aspergillus* kit could be to combine it with another surrogate marker of IA in an attempt to complement the diagnostic usefulness of GM detection. The results presented in this paper appear to suggest that BG may be such a complementary marker since the combination of BG and GM detection was more effective than either test alone in diagnosing IA.

The information about the diagnostic potential of BG for the diagnosis of IA is currently scarce. In most studies, BG detection has been used as a tool for screening IFI. An early study by Obayashi et al. (23), published a decade ago, showed that cases of deep mycoses were associated with high concentrations of BG in plasma as measured by the FungiTec G test. In their study of over 200 febrile episodes in patients with hematological malignancy, they were able to detect 37 of 41 cases of IFI by using a cutoff of 20 pg/ml. An interesting feature of their study is that fungal superficial colonization (including oral, urinary, and bronchial colonization) did not raise the concentration of BG above 20 pg/ml. Four patients with *Aspergillus* pneumonia verified at autopsy had high concentrations of BG in plasma.

Several studies have reported that the sensitivity of BG detection for diagnosing IFI ranges between 50 and 63% (12, 13, 29). This is in contrast to data presented in this study, which show that detection of BG by the GlucateLL test is a quite sensitive tool for the diagnosis of IA (87.5%). The high sensitivity observed in our study could be inherent to the GlucateLL test, since commercialized tests for BG detection differ widely in sensitivity (13, 38). A preliminary evaluation of the GlucateLL test has shown sensitivities between 60 and 100% for the diagnosis of IFI in patients with acute myeloid leukemia or myelodysplastic syndrome who were receiving antifungal prophylaxis (24). Although the existence of differences in the kinetics of BG release during invasive growth by *Aspergillus* and other fungi causing IFI cannot be ruled out at present, it is possible that the frequency of sampling in our study (twice weekly) may have increased the sensitivity of the test, since some studies have detected BG on a once-a-week basis or once per episode (13, 23). Odabasi et al. (24) used a cutoff of 60 pg/ml with the aim of detecting patients with IFI. The use of that cutoff for our patients would have decreased the specificity and positive predictive value in comparison with values obtained when using 120 pg/ml. Currently, the kinetics of BG release from the infected sites and its circulation in blood and clearance are poorly understood. The kinetics shown in this study suggest that an increase in the concentration of BG from 60 to greater than 360 pg/ml (Fig. 1a) and from 90 to 120 pg/ml (Fig. 2b) can occur in the course of 5 days. Therefore, a twice-weekly sampling seems to be a reasonable frequency for a BG screening strategy.

BG was consistently negative in one patient with probable IA (who had received prophylaxis with fluconazole) and two patients with possible IA (who had received no prophylaxis).

TABLE 4. Temporal onset of GM antigenemia in patients with proven and probable IA

Time point <sup>a</sup>	No. of evaluable patients	No (%) of patients with GM antigen	Days between GM antigen detection and time point median (range)
First day of fever	7	1 (14.3)	4 (4)
First day of clinical signs <sup>b</sup>	7	3 (42.8)	9 (4–15)
Pulmonary HRCT scan	7	6 (85.7)	7.2 (1–15)
Initiation of antifungal therapy	7	4 (57.1)	12.5 (1–23)

<sup>a</sup> At or before time point.<sup>b</sup> Cough and/or dyspnea and/or hemoptysis and/or thoracic pain.

Although the IA episodes were classified in this study on the basis of the EORTC-IFICG/NIAID-MSG case definitions (1), it cannot be excluded that the clinicrodiological pictures of the patients were due to a variety of nonfungal diseases. In fact, the clinical applicability of EORTC-IFICG/NIAID-MSG case definitions is controversial, as has been recently shown (30). Interestingly, these three patients were also negative by GM detection.

One of the problems observed in the detection of BG is the existence of false-positive results that decrease the specificity of the test (13). The reason for the BG positivity in the three patients with false-positive results remains obscure. While none of them was undergoing hemodialysis with cellulose membranes, a well-known cause of false-positive results in BG detection tests (22, 23), one of the patients had *E. coli* bacteremia and the other two were colonized by *Candida* species. However, *Candida* colonization is unlikely to be the cause of the false-positive results, since other patients with intense colonization by *Candida* species had negative BG levels (Fig. 1e and f), and it has been reported that isolation of a number of bacteria in blood, as well as colonization by yeasts, did not produce BG positive results by the FungiTec G test (23). In addition, neither *Candida*-colonized patient had antibodies to CAGT, which is a marker of invasive candidiasis (9). Since BG is a panfungal marker that could detect undiagnosed fungal infections, the possibility of an infection caused by a number of unusual fungal species such as *Trichosporon* spp., *Saccharomyces* spp., *Acremonium* spp., and *P. jiroveci* cannot be totally ruled out. An interesting feature of the kinetics of BG levels in patients with false-positive results is the sudden rise and fall in BG levels in serum in the absence of antifungal treatment (Fig. 1c). This type of kinetics is also shared by false-positive GM results (33), while a more protracted rise in BG levels in serum suggests the presence of *Aspergillus* infection, as shown in Fig. 1a and b.

Detection of circulating surrogate markers of IA may be useful not only for the diagnosing the mycosis but also for assessing the effectiveness of therapy. This has been demonstrated for GM antigenemia, since declining levels of GM have been found in patients responding to treatment while rising GM antigenemia is associated with treatment failure (2, 3, 17, 25). Results presented in this study show, for the first time, that monitoring BG antigenemia is useful in predicting the therapeutic outcome of patients with IA. Decreasing levels of BG were observed in patients who recovered from IA, while patients not responding to antifungal treatment showed a continuous rise in serum BG levels.

Although it did not improve the sensitivity of each test, the combination of BG and GM detection was very useful in confirming the existence of IA, since both markers were positive in patients with IA and, as expected for two cell wall molecules, their kinetics of release to the blood was very similar. Given the concordance of the two markers in patients with IA, discrepancies in positivity by each test were very useful in identifying false-positive results by each test. If this concordance in positivity is confirmed in other studies, combined detection of BG and GM may be an important tool to solve the problem raised by the false-positive results detected by each test (8, 13, 20).

Although the sensitivities were equal for both markers and

both tests are usually positive before the diagnosis of IA could be suspected or demonstrated by other means, results presented in this study suggest that BG tended to become positive earlier than GM (Tables 3 and 4). This precocity, and the fact that BG can also be a marker of invasive infections caused by a number of different fungi, should lead to initiation of the diagnostic workup of IFI when a positive BG result is detected and should enable prompt provision of preemptive antifungal treatment with a broad-spectrum antifungal drug. BG positivity should be confirmed by GM detection or by detection of antibodies to CAGT (9) and, when available, by PCR to identify the type of IFI and to exclude the possibility of a false-positive result.

In conclusion, BG and GM detection are useful tests for the diagnosis of IA in high-risk patients with hematological malignancies. However, a combination of the two tests was very useful to identify false-positive reactions by each test. The results presented in this study encourage a prospective evaluation of the GlucateLL test to assess its role in the diagnosis of IA and follow-up of patients at high risk for developing this disease.

#### ACKNOWLEDGMENTS

This investigation was supported by grants v-iig-27 from Fundación Fundesa (to A.D.P.) and 9/UPV 0093.327-13550/2001 from the Universidad del País Vasco (to J.P.).

We thank Pelayo Fontsaré and Marta Pérez from Fontlab 2000 Santa Eulalia de la Ronçana, Barcelona, Spain, for their technical help with the detection of BG.

#### REFERENCES

1. Asciglu, S., J. H. Rex, B. de Pauw, J. E. Bennett, J. Bille, F. Crokaert, D. W. Denning, J. P. Donnelly, J. E. Edwards, Z. Erjavec, D. Fiere, O. Lortholary, J. Maertens, J. F. Meis, T. F. Patterson, J. Ritter, D. Selleslag, P. M. Shah, D. A. Stevens, and T. J. Walsh. 2002. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. *Clin. Infect. Dis.* 34:7–14.
2. Boutboul, F., C. Alberti, T. Leblanc, A. Sulahian, E. Gluckman, F. Derovin, and P. Ribaud. 2002. Invasive aspergillosis in allogeneic stem cell transplant recipients: increasing antigenemia is associated with progressive disease. *Clin. Infect. Dis.* 43:939–943.
3. Bretagne, S., A. Marmorat-Khvang, M. Kventz, J. P. Latgé, E. Bart-Delabasse, and C. Cordonnier. 1997. Serum *Aspergillus* galactomannan antigen testing by sandwich ELISA: a practical use in neutropenic patients. *J. Infect. Dis.* 35:7–15.
4. Del Palacio, A., M. S. Cuétara, and J. Pontón. 2003. La aspergilosis invasora. *Rev. Iberoam. Micol.* 20:77–78.
5. Del Palacio, A., M. S. Cuétara, and J. Pontón. 2003. El diagnóstico de laboratorio de la aspergilosis invasora. *Rev. Iberoam. Micol.* 20:90–98.
6. Denning, D. W., E. G. Evans, C. C. Kibbler, M. D. Richardson, M. M. Roberts, T. R. Rogers, D. W. Warnock, and R. E. Warren. 1997. Guidelines for the investigation of invasive fungal infections in haematological malignancy and solid organ transplantation. *Eur. J. Clin. Microbiol. Infect. Dis.* 16:424–436.
7. Denning, D. W., A. Marinus, J. Cohen, D. Spence, R. Herbrecht, L. Pagano, C. Kibbler, V. Kermery, F. Offner, C. Cordonnier, U. Jehn, M. Ellis, L. Collette, and R. Sylvester. 1998. An EORTC multicentre prospective survey of invasive aspergillosis in haematological patients: diagnosis and therapeutic outcome. *J. Infect.* 37:173–180.
8. Digby, J., J. Kalbfleisch, A. Glenn, A. Larsen, W. Browder, and D. Williams. 2003. Serum glucan levels are not specific for presence of fungal infections in intensive care unit patients. *Clin. Diagn. Lab. Immunol.* 10:882–885.
9. García-Ruiz, J. C., M. C. Arilla, P. Regúlez, G. Quindós, A. Alvarez, and J. Pontón. 1997. Detection of antibodies to *Candida albicans* germ tubes for the diagnosis and therapeutic monitoring of invasive candidiasis in patients with hematologic malignancies. *J. Clin. Microbiol.* 35:3284–3287.
10. Jantunen, E., P. Ruutu, L. Niskanen, L. Volin, T. Parkkali, P. Koukila-Kahkola, and T. Ruutu. 1997. Incidence and risk factors for invasive fungal infections in allogeneic BMT recipients. *Bone Marrow Transplant.* 19:801–808.
11. Jones, B. L., and L. A. McIntock. 2003. Impact of diagnostic markers on early antifungal therapy. *Curr. Opin. Infect. Dis.* 16:521–526.

12. Kami, M., Y. Tanaka, Y. Kanda, S. Ogawa, T. Masumoto, K. Ohtomo, T. Matsumura, T. Saito, U. Machida, T. Kashima, and H. Hirai. 2000. Computer tomographic scan of the chest, latex agglutination test and plasma (1→3)-β-D-glucan assay in early diagnosis of invasive pulmonary aspergillosis: a prospective study of 215 patients. *Haematologica* **85**:745–752.
13. Kawazu, M., Y. Kanda, Y. Nannya, K. Aoki, M. Kurokawa, S. Chiba, T. Motokura, H. Hirai, and S. Ogawa. 2004. Prospective comparison of the diagnostic potential of real-time PCR, double-sandwich enzyme-linked immunosorbent assay for galactomannan, and (1→3)-β-D-glucan test in weekly screening for invasive aspergillosis in patients with hematological disorders. *J. Clin. Microbiol.* **42**:2733–2741.
14. Kozinn, P. J., C. L. Taschdjian, P. K. Goldberg, W. P. Protzmann, D. W. R. Mackenzie, J. S. Remington, S. Anderson, and M. S. Seelig. 1978. Efficiency of serologic tests in the diagnosis of systemic candidiasis. *Am. J. Clin. Pathol.* **70**:893–898.
15. Lin, S. J., J. Schranz, and S. M. Teutsch. 2001. Aspergillosis case-fatality rate: systematic review of the literature. *Clin. Infect. Dis.* **32**:358–366.
16. Maertens, J., J. Van Eldere, J. Verhaegen, E. Verbeken, J. Verschakelen, and M. Boogaerts. 2002. Use of circulating galactomannan screening for early diagnosis of invasive aspergillosis in allogeneic stem cell transplant recipients. *J. Infect. Dis.* **186**:1297–1306.
17. Maertens, J., J. Verhaegen, H. Demuyne, P. Brock, G. Verhoef, P. Vandenberghe, J. Van Eldere, L. Verbist, and M. Boogaerts. 1999. Autopsy-controlled prospective evaluation of serial screening for circulating galactomannan by a sandwich enzyme-linked immunosorbent assay for hematological patients at risk for invasive aspergillosis. *J. Clin. Microbiol.* **37**:3223–3228.
18. Maertens, J., J. Verhaegen, K. Lagrou, J. Van Eldere, and M. Boogaerts. 2001. Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation. *Blood* **97**:1604–1610.
19. Marr, K. A., R. A. Carter, M. Boeckh, P. Martin, and L. Corey. 2002. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. *Blood* **100**:4358–4366.
20. Mennink-Kersten, M. A. S. H., J. P. Donnelly, and P. E. Verweij. 2004. Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis. *Lancet Infect. Dis.* **4**:349–357.
21. Miyazaki, T., S. Kohno, K. Mitsutake, S. Maesaki, K. Tanaka, N. Ishikawa, and K. Hara. 1995. Plasma (1→3)-beta-D-glucan and fungal antigenemia in patients with candidemia, aspergillosis, and cryptococcosis. *J. Clin. Microbiol.* **33**:3115–3118.
22. Obayashi, T., T. Tamura, S. Tamaka, M. Onki, S. Takahashi, and T. Kawai. 1986. Endotoxin-inactivating activity in normal and pathological human blood samples. *Infect. Immun.* **53**:294–297.
23. Obayashi, T., M. Yoshida, T. Mori, H. Goto, A. Yasuoka, H. Iwasaki, H. Teshima, S. Kohno, A. Horiuchi, A. Ito, H. Yamaguchi, K. Shimada, and T. Kawai. 1995. Plasma (1→3)-beta-D-glucan measurement in diagnosis of invasive deep mycosis and fungal febrile episodes. *Lancet* **345**:17–20.
24. Odabasi, Z., G. Mattiuzzi, E. Estey, H. Kantarjian, F. Saeki, R. J. Ridge, P. A. Ketchum, M. A. Finkelman, J. H. Rex, and L. Ostrosky-Zeichner. 2004. β-D-Glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. *Clin. Infect. Dis.* **39**:199–205.
25. Pazos, C., and A. del Palacio. 2003. Diagnóstico precoz de la aspergilosis invasora en enfermos neutropénicos mediante la detección bisemanal de galactomanano en suero con Platelia *Aspergillus*. *Rev. Iberoam. Micol.* **20**:99–102.
26. Perfect, J. R., G. M. Cox, J. Y. Lee, C. A. Kauffman, L. de Repentigny, S. W. Chapman, V. A. Morrison, P. Pappas, J. W. Hiemenz, and D. A. Stevens. 2001. The impact of culture isolation of *Aspergillus* species: a hospital-based survey of aspergillosis. *Clin. Infect. Dis.* **33**:1824–1833.
27. Prentice, H. G., C. C. Kibbler, and A. G. Prentice. 2000. Towards a targeted, risk-based, antifungal strategy in neutropenic patients. *Br. J. Haematol.* **110**:273–284.
28. Ruhnke, M., and G. Maschmetes. 2002. Management of mycoses in patients with hematologic disease and cancer-review of the literature. *Eur. J. Med. Res.* **7**:227–235.
29. Sakai, T., K. Ikegami, E. Yoshinaga, R. Uesugi-Hayakawa, and A. Wakizaka. 2000. Rapid, sensitive and simple detection of candida deep mycosis by amplification of 18S ribosomal RNA gene: comparison with assay of serum beta-D-glucan level in clinical samples. *Tohoku J. Exp. Med.* **190**:119–128.
30. Subirá, M., R. Martino, M. Rovira, L. Vázquez, D. Serrano, and R. de la Cámara. 2003. Clinical applicability of the new EORTC/MSG classification for invasive pulmonary aspergillosis in patients with hematological malignancies and autopsy-confirmed invasive aspergillosis. *Ann. Hematol.* **82**:80–82.
31. Sulahian, A., F. Boutboul, P. Ribaud, T. Leblanc, C. Lacroix, and F. Derouin. 2001. Value of antigen detection using an enzyme immunoassay in the diagnosis and prediction of invasive aspergillosis in two adult and pediatric hematology units during a 4-year prospective study. *Cancer* **91**:311–318.
32. Sulahian, A., M. Tabouret, P. Ribaud, J. Sarfati, E. Gluckman, J. P. Latgé, and F. Derouin. 1996. Comparison of an enzyme immunoassay and latex agglutination test for detection of galactomannan in the diagnosis of invasive aspergillosis. *Eur. J. Clin. Microbiol. Infect. Dis.* **15**:139–145.
33. Swanink, C. M. A., J. F. G. Meis, A. J. M. M. Rijs, J. P. Donnelly, and P. E. Verweij. 1997. Specificity of a sandwich enzyme-linked immunosorbent assay for detecting *Aspergillus* galactomannan. *J. Clin. Microbiol.* **35**:257–260.
34. Verweij, P. E., and D. W. Denning. 1997. The challenge of invasive aspergillosis: increasing numbers in diverse patient groups. *Int. J. Infect. Dis.* **2**:61–63.
35. Verweij, P. E., E. C. Dompeling, J. P. Donnelly, A. V. Schattenberg, and J. F. Meis. 1997. Serial monitoring of *Aspergillus* antigen in the early diagnosis of invasive aspergillosis. Preliminary investigations with two examples. *Infection* **25**:86–89.
36. Verweij, P. E., J. P. Latgé, A. J. Rijs, W. J. Melchers, B. E. De Pauw, J. A. Hoogkamp-Korstanje, and J. F. Meis. 1995. Comparison of antigen detection and PCR assay using bronchoalveolar lavage fluid for diagnosing invasive pulmonary aspergillosis in patients receiving treatment for hematological malignancies. *J. Clin. Microbiol.* **33**:3150–3153.
37. von Eiff, M., N. Roos, R. Schulten, M. Hesse, M. Zuhlsdorf, and J. van de Loo. 1995. Pulmonary aspergillosis: early diagnosis improves survival. *Respiration* **62**:341–347.
38. Yoshida, K., Y. Niki, H. Mitekura, M. Nakajima, H. Kawane, and T. Matsushima. 2001. A discrepancy in the values of serum (1→3)-beta-D-glucan measured by two kits using different methods. *Nippon Ishinkin Gakkai Zasshi* **42**:237–242. (In Japanese.)